GlassScriptPhysician profile
Patrick Litonjua
NPI 1831297308
$760.87
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.42 · 2020: $138 · 2021: $128 · 2022: $240 · 2023: $107 · 2024: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $250.45 | 2021-2024 | |
| Abbott Laboratories | $114.21 | 2019-2022 | |
| Amgen INC. | $101.38 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.86 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $48.23 | 2020-2021 | |
| Medtronic, INC. | $39.51 | 2024 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Insulet Corporation | $29.36 | 2021 | |
| Kyowa Kirin, INC. | $25.22 | 2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $21.71 | 2023 | Recorlev |
| Boston Scientific Corporation | $17.15 | 2022 | |
| Antares Pharma, INC. | $15.59 | 2023 | Nocdurna, Xyosted, Tlando |
| Amneal Pharmaceuticals LLC | $13.68 | 2019 | |
| Medtronic Minimed, INC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Litonjua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.